Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.

ABSTRACT:

Background

Ewing sarcoma/PNET is managed with treatment paradigms involving combinations of chemotherapy, surgery, and sometimes radiation. Although the 5-year survival rate of non-metastatic disease approaches 70%, those cases that are metastatic and those that recur have 5-year survival rates of less than 20%. Molecularly targeted treatments offer the potential to further improve treatment outcomes.

Methods

A PUBMED search was performed from 1997 to 2011. Published literature that included the topic of the Ewing sarcoma/PNET was also referenced.

Results

Insulin-like growth factor-1 receptor (IGF-1R) antagonists have demonstrated modest single agent efficacy in phase I/II clinical trials in Ewing sarcoma/PNET, but have a strong preclinical rationale. Based on in vitr

SUBMITTER: Kelleher FC 

PROVIDER: S-EPMC3351706 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature